qualitative research grounded in SEC filings & market-flow signals Quant side · QuantOrb.pro ↗

TMO — Tear Sheet

THERMO FISHER SCIENTIFIC INC.

covers US session 2026-10-23 · Tear sheet created 21 days ago

AdCho Opinion

Hold

Bottom Line

Hold: the print confirms the compounder with high-single-digit revenue growth and double-digit adjusted EPS, while the tape sits under its short-term EMA with a widening MACD histogram and the macro tripwire a hair away

Market Sentiment Summary

The sentiment report reads Bullish, scored 7.0 out of 10, at medium confidence — a cap we keep.

TMO daily chart

sessions

Loading chart…

How to read this chart
  1. Top: price candles (green up, red down) with Bollinger Bands (20, 2) in dashed orange, the 50-session average in blue, the 200-session average in dashed orange, and volume bars along the bottom
  2. Middle: RSI (14), Wilder’s method, with dashed guides at 30 and 70
  3. Bottom: MACD (12, 26, 9): MACD line, dashed signal line and a green/red histogram

Prices: Yahoo Finance daily bars, split- and dividend-adjusted; indicators computed on two years of history, then the window is cut · as of latest session · Chart by TradingView Lightweight Charts™ © TradingView, Inc.

Share this tear sheet

X Facebook LinkedIn Reddit WhatsApp Email

Executive Summary

  • We read this as a Hold: the verified quarter wins the business case while an un-bottomed, macro-pressured tape loses the entry case
  • Operating delivery is the constructive spine: high-single-digit revenue growth, mid-single-digit organic, and adjusted EPS up double digits
  • The tape is the counterweight: price under the short-term EMA with a widening MACD histogram and bearish divergences at the double top
  • Macro clinches the stand-off — the 10-year a hair under its flagged threshold with inflation re-accelerating and volatility in a higher regime
  • The regime is still up — price well above a rising long-term average with fading sell volume — so we see no sell case
  • The stance is enforceable, not passive: add on a reclaim of the short-term average, trim on a daily close through the stated de-risk line

Market Sentiment

  • Our reading is Bullish at seven of ten with medium confidence, capped by an extended setup and mostly unusable social data
  • The news leg carried the week — a clean beat, a wall of raised street marks — yet the stock opened down on the print
  • Sell-side conviction was partial: some banks raised marks sharply while still withholding rating upgrades, and the low outlier sat near the closing price
  • Retail chatter ran unanimously positive — zero bearish tags in a tiny sample — which our contrarian lens flags at record highs
  • The X lane contributed nothing measurable: a near-identical promo swarm with no engagement buried two tangential organic posts
  • The forum channel was silent, so the social leg rests on the retail message flow alone, and we weight it light against the verified print

News

get_global_news

Stock market today: Dow sinks 600 points, S&P 500, Nasdaq drop to cap a volatile week, oil prices rise

The week's cap: a volatile tape ended with the Dow sinking 600 points and broad indices lower on a tech-led sell-off.

AdCho insight: This is the macro constraint behind the Hold: a strong print met a tape where the broad market was selling, so the entry case stays weak even as the business case holds.

get_global_news

Dow and Small Caps Climb Weekly While Nasdaq Slips on Megacap Earnings Charges

The weekly wrap: losses concentrated in megacap tech on earnings charges while other sleeves held up.

AdCho insight: The damage was tech-led rather than broad, which fits the week's framing of TMO as a rotation beneficiary out of AI — a defensive-quality read consistent with the sheet's macro caution.

get_news

Should Illumina Stock Holders Look At Thermo Fisher Instead?

A relative-value argument steering Illumina holders toward Thermo Fisher, part of the week's constructive peer framing around the tools group.

AdCho insight: Peer-preference coverage supports the business-quality leg of the Hold; it speaks to franchise strength, not entry timing, which is where the sheet stands off.

get_news

Thermo Fisher Scientific (TMO) Benefits on Broad-Based Recovery Across Life-Science Markets

Coverage of the quarter's breadth — pharma and biotech demand with instruments and consumables recovering across life-science end markets.

AdCho insight: Independent corroboration for the operating-delivery leg the sheet's fundamental case rests on: broad-based end-market recovery behind the reported growth.

get_news

NGS Kits Market Forecasts Growth from $6.84 Billion (2025) to $19.36 Billion by 2036, Profiling Illumina, Thermo Fisher Scientific, Roche, Oxford Nanopore & 11 Other Key Players

A long-horizon market forecast profiling Thermo Fisher among key players, one of the structural demand pools the week's coverage flagged alongside GLP-1 peptide demand.

AdCho insight: Structural demand pools underwrite the strategic thesis that keeps the sheet holding rather than selling, separate from the weak entry point.

get_news

Clinical Laboratory Molecular Diagnostics for Infectious Diseases Market, 2025-2029: Forecast by Application, Place, and Country | Multiplex and Rapid Testing Unlock Growth

A sector forecast on multiplex and rapid testing growth, mapping onto the diagnostics franchises the quarter's coverage highlighted.

AdCho insight: More demand-pool color behind the compounder case; the sheet treats these long-horizon forecasts as context, not a near-term driver.

Social

metavestor

5 bio AI stocks for the next decade? So much is going to change year by year. I don't think anyone truly knows the shape of what bio x AI endgame will look like yet (though I have my guesses). To answer the q at face value, the tools companies $TMO $DHR $TXG $BRKR $RVTY give https://t.co/HTGRGgDN8F

2026-10-24

AdCho insight: Retail-level AI-adoption framing that echoes the quarter's AI-integration theme, but tangential and thin — color for the strategic thesis, not weight.

directorblue

@AndrewCurran_ Supply chain ideas? $DHR $RXRX $TMO $TEM Bachem ?

2026-10-24

AdCho insight: The ticker stays in retail watchlists for supply-chain exposure; with no substance behind it, the X lane adds no measurable sentiment weight to the sheet.

Polymarket

Will no Fed rate cuts happen in 2026?
Yes 96% ($9,108,579 volume, resolves 2027-01-01, 1-week -0.4pp)

Will 11 Fed rate cuts happen in 2026?
Yes 0% ($5,319,017 volume, resolves 2027-01-01)

Will 10 Fed rate cuts happen in 2026?
Yes 0% ($4,973,199 volume, resolves 2027-01-01)

Will 9 Fed rate cuts happen in 2026?
Yes 0% ($4,308,913 volume, resolves 2027-01-01)

Will 6 Fed rate cuts happen in 2026?
Yes 0% ($4,232,530 volume, resolves 2027-01-01)

Will 12 or more Fed rate cuts happen in 2026?
Yes 0% ($4,156,117 volume, resolves 2027-01-01)

Live odds at run time (UTC) — macro market context, not company-specific; the rates, recession and fiscal-deadline odds every equity reads against. Not signals to act on. Topic: “Fed rate cut”.

Management Sentiment & Catalyst Highlights

  • Chief executive Marc Casper called it "another excellent quarter," crediting growth strategy and PPI execution for the delivery
  • The company credited its growth strategy and PPI Business System for execution, and launched a range of new products in the quarter
  • Guidance direction was affirmed — well positioned to deliver an excellent year — while the level itself stayed put
  • The street chased the print — eight banks lifted marks within two days, though two skeptics marked up while withholding conviction
  • Visible catalysts: the upcoming fourth-quarter print and whether the excellent-year framing holds, plus consolidation ripple effects across life-science tools after the Qiagen takeover
  • Capital deployment continued under the growth strategy, though a large early-year acquisition was never underwritten in what we hold

Key Risk Factors

  • The primary risk is momentum: price under the short-term EMA with a widening MACD histogram and bearish divergences at the double top
  • Gap risk is live — the widest ATR of the year and a down-open on the print show stops can be overshot
  • Macro is the second leg: the 10-year a hair under its tripwire, inflation re-accelerating, and a volatility regime well above September's
  • Growth-quality caveats temper the fundamental leg: buybacks roughly double EPS growth against net income, free cash flow fell last year, and liquidity ratios eased
  • Evidence quality is the quiet risk: holdings are stale and mixed, the zero-bear retail read is contrarian, and margin detail traces to unverified recaps
  • The counterweight to the bearish tape: prior divergences here resolved as consolidation, and fading sell volume with a rising long-term average keeps the regime intact

QuantOrb.pro Quantitative Signals

MFI (14-day)

65.01

accumulation zone · None screen

qOp signal strength

NONE · 43%

quantitative screen, not a recommendation

Revenue

$12.14B

+9%

Organic growth

6%

Diluted EPS

$4.64

+9%

Adjusted EPS

$6.68

+15%

Money-flow and momentum readings from this run's own engine outputs (QuantOrb snapshot as cited in Sources; technicals as of the covered session) — context, not signals to act on.

Not a recommendation. A quantitative screen, not a recommendation — the 13F data are a non-exhaustive quarter-end snapshot subject to a reporting lag of up to 45 days.

qOp quant view →

Sources

Facts (verifiable): SEC filings via the QuantOrb document corpus · QuantOrb money-flow & 13F datasets. Reading (AI-powered): AdCho’s synthesis via a multi-analyst AI engine.

Sheet schema adcho.tearsheet.v1 · rendered by AdCho · freshness day 21 (D11 day-0 rule, US-session dates only)